Eli Lilly invites you to an informative session on the role of Mounjaro in the early holistic management of type 2 diabetes, featuring international endocrinologists Prof. Santiago Tofé and Dr. Ilaria Dicembrini. The experts will discuss the impact of Mounjaro on both HbA1c reduction and weight loss in phase 3 clinical trials, while also highlighting how addressing excess weight early may offer greater clinical benefits than focusing on glycemic control alone.
Join us on April 15 , 2026 , to explore how Mounjaro can support a more comprehensive, real-world approach to type 2 diabetes management for your patients. Session 1 : 2:30 PM – 3:30 PM Session 2 : 10:00 PM – 11:00 PM We look forward to an engaging and insightful discussion with you. Click here to view Mounjaro API . Therapeutic indication Type 2 diabetes mellitus MOUNJARO® is indicated for the treatment of adults with…
